Latest P53 Stories
The American Cancer Society estimates there will be more than 200,000 new cases of invasive breast cancer in women and 39,000 deaths, this year alone.
Metastasizing cancer cells often express integrins that provide better traction.
The expression of p53 and Mdm2 is closely related. In an article published this week in the Cancel Cell review, Robin Fahraeus and his collaborators from Inserm Unit 940 ("Therapeutic Targets for Cancer"), demonstrate that cellular response to DNA damage requires involvement from the protein kinase ATM so that Mdm2 can positively or negatively control protein p53.
Cholesterol lowering statins seem to be effective against breast cancer in some patients. Research shows that a mutation in a single gene may be a way for researchers to identify tumors that are likely to respond to statin therapy.
Cholesterol-lowering statins seem to keep breast cancer at bay in some patients.
An inherited mutation in a gene known as the guardian of the genome is likely the link between exploding chromosomes and some particularly aggressive types of cancer, scientists at the European Molecular Biology Laboratory (EMBL), the German Cancer Research Centre (DKFZ) and the University Hospital, all in Heidelberg, Germany, have discovered.
A well-known protein complex responsible for controlling how DNA is expressed plays a previously unsuspected role in preventing pancreatic cancer.
Either heart failure or diabetes alone is bad enough, but oftentimes the two conditions seem to go together.
For years, science has generally considered the phosphorylation of proteins -- the insertion of a phosphorous group into a protein that turns it on or off -- as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death.